Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 327Neoplasm Metastasis 31Advanced Breast Cancer 19Neoplasms 17Ovarian Neoplasms 11Hereditary Sensory and Autonomic Neuropathies 10Triple Negative Breast Neoplasms 8Prostatic Neoplasms 7Endometrial Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Cancer Metastatic 6Uterine Cervical Neoplasms 5Breast Diseases 5Squamous Cell Carcinoma of Head and Neck 4Neoplasms by Site 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Small Cell Lung Carcinoma 3Recurrence 3Multiple Endocrine Neoplasia Type 1 3Head and Neck Neoplasms 3Breast Neoplasm Female 3Uterine Neoplasms 2Stomach Neoplasms 2Pancreatic Neoplasms 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Liposarcoma 2Hyperglycemia 2HER2-positive Metastatic Breast Cancer 2HER2-positive Breast Cancer 2

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Breast Carcinoma × Fulvestrant × Breast × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡